| Citation: |
JIANG Xiaozhen, GUO Fengfen, SHENG Yiyun, LIANG Shengnan, WAN Hongping, DENG Kui. Clinicopathological Analysis of 11 Cases of SMARCA4 (BRG1)-deficient Carcinoma[J]. Cancer Research on Prevention and Treatment, 2024, 51(6): 469-474. DOI: 10.3971/j.issn.1000-8578.2024.23.1121
|
To investigate the clinicopathological features, immunophenotype, diagnosis and treatment of SMARCA4 (BRG1)-deficient carcinoma.
Clinical data of 11 patients with SMARCA4 (BRG1)-deficient cancer were collected. The morphologic and immunohistochemical features of this tumour were summarized, and the relevant literature was reviewed.
Among the 11 cases of SMARCA4 (BRG1)-deficient carcinoma, eight were male and three were female, with median age of 60. Seven patients underwent radical resection, and four underwent traditional joint targeted chemotherapy and immunotherapy. Microscopically, the tumor cells were epithelioid, rhabdoid or spindle-shaped, with prominent eosinophilic nucleoli and frequent mitoses (>5/10 HPF). Multiple foci of necrosis were found in the tumor tissue, a large number of tumor emboli in the blood vessels and myxoid stromal degeneration. Among these cases, 11 cases showed loss of SMARCA4 (BRG1) expression, whereas the CK and Vim markers were expressed, SMARCB1 (INI1) expression was retained, and p53 mutation was detected. The tumor cells showed high proliferation activity (Ki-67>60%), and synaptophsin was moderately positive. Three cases were mismatch repair deficient and respectively showed the loss of MLH1/PMS2, PMS2 and MSH6 expression.
The incidence of SMARCA4 (BRG1) -dificient carcinoma is low. It can be easily confused with other tumors and is difficult to be diagnosed before operation, which requires confirmation by immunohistochemistry.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Jelinic P, Mueller JJ, Olvera N, et al. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary[J]. Nat Genet, 2014, 46(5): 424-426. doi: 10.1038/ng.2922
|
| [2] |
La Fleur L, Falk-Sörqvist E, Smeds P, et al. Mutation patterns in apopulation based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11[J]. Lung Cancer, 2019, 130: 50-58. doi: 10.1016/j.lungcan.2019.01.003
|
| [3] |
Sirohi D MD, Ohe C, Smith SC, et al. SWI/SNF-deficient neoplasms of the genitourinary tract[J]. Semin Diagn Pathol, 2021, 38(3): 212-221. doi: 10.1053/j.semdp.2021.03.007
|
| [4] |
Fernando TM, Piskol R, Bainer R, et al. Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131, 668 cancer patients[J]. Nat Commun, 2020, 11(1): 5551. doi: 10.1038/s41467-020-19402-8
|
| [5] |
Peterson CL, Dingwall A, Scott MP. Five SWI/SNF gene products are components of a large multisubunit complex required for transcriptional enhancement[J]. Proc Natl Acad Sci U S A, 1994, 91(8): 2905-2908. doi: 10.1073/pnas.91.8.2905
|
| [6] |
Masliah-Planchon J, Bièche I, Guinebretière JM, et al. SWI/SNF chromatin remodeling and human malignancies[J]. Annu Rev Pathol, 2015, 10: 145-171. doi: 10.1146/annurev-pathol-012414-040445
|
| [7] |
Agaimy A. The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity[J]. Adv Anat Pathol, 2014, 21(6): 394-410. doi: 10.1097/PAP.0000000000000038
|
| [8] |
朱培培, 李新星, 刘佳涵, 等. 胃肠道SMARCA4缺失性未分化癌9例临床病理学分析[J]中华病理学杂志, 2022, 51(9): 868-874. [Zhu PP, Li XX, Liu JH, et al. SMARCA4-deficient undifferentiated carcinoma of the gastrointestinal tract: a clinicopathological and immunohistochemical study of nine cases[J]. Zhonghua Bing Li Xue Za Zhi, 2022, 51(9): 868-874.]
Zhu PP, Li XX, Liu JH, et al. SMARCA4-deficient undifferentiated carcinoma of the gastrointestinal tract: a clinicopathological and immunohistochemical study of nine cases[J]. Zhonghua Bing Li Xue Za Zhi, 2022, 51(9): 868-874.
|
| [9] |
Chang B, Sheng W, Wang L, et al. SWI/SNF complex-deficient undifferentiated carcinoma of the gastrointestinal tract: clinicopathologic study of 30 cases with an emphasis on variable morphology, immune features, and the prognostic significance of different SMARCA4 and SMARCA2 subunit deficiencies[J]. Am J Surg Pathol, 2021, 46(7): 889-906.
|
| [10] |
黄榕芳, 何诚, 朱伟峰, 等. SMARCA4缺失肠癌的临床病理学及分子特征[J]中华病理学杂志, 2021, 50(4): 382-384. [Huang RF, He C, Zhu WF, et al. Clinicopathological and molecular features of SMARCA4-deficient carcinoma of the intestinal tract[J]. Zhonghua Bing Li Xue Za Zhi, 2021, 50(4): 382-384.]
Huang RF, He C, Zhu WF, et al. Clinicopathological and molecular features of SMARCA4-deficient carcinoma of the intestinal tract[J]. Zhonghua Bing Li Xue Za Zhi, 2021, 50(4): 382-384.
|
| [11] |
Tsuruta S, Kohashi K, Yamada1 Y, et al. Solid-type poorly differentiated adenocarcinoma of the stomach: Deficiency of mismatch repair and SWI/SNF complex[J]. Cancer Sci, 2020, 111(3): 1008-1019. doi: 10.1111/cas.14301
|
| [12] |
Tessier-Cloutier B, Kang EY, Alex D, et al. Endometrial neuroendocrine carcinoma and undifferentiated carcinoma are distinct entities with overlap in neuroendocrine marker expression[J]. Histopathology, 2022, 81(1): 45-54.
|
| [13] |
Machado I, Yoshida A, Morales MGN, et al. Review with novel markers facilitates precise categorization of 41 cases of diagnostically challenging, "undifferentiated small round cell tumors". A clinicopathologic, immunophenotypic and molecular analysis[J]. Ann Diagn Pathol, 2018, 34(7): 1-12.
|
| [14] |
Naito T, Udagawa H, Umemura S, et al. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden[J]. Lung Cancer, 2019, 138: 35-42. doi: 10.1016/j.lungcan.2019.10.009
|
| [15] |
Bell EH, Chakraborty AR, Mo X, et al. SMARCA4/BRG1 is a novel prognostic biomarker predictive of cisplatin-based chemotherapy outcomes in resected non-small cell lung cancer[J]. Clin Cancer Res, 2016, 22(10): 2396-2404. doi: 10.1158/1078-0432.CCR-15-1468
|
| [16] |
Schoenfeld AJ, Bandlamudi C, Lavery JA, et al. The genomic landscape of SMARCA4 alterations and associations with outcomes in Patients with lung cancer[J]. Clin Cancer Res, 2020, 26(21): 5701-5708. doi: 10.1158/1078-0432.CCR-20-1825
|
| [17] |
Takada K, Sugita S, Murase K, et al. Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: a case report[J]. Thorac Cancer, 2019, 10(12): 2312-2315. doi: 10.1111/1759-7714.13215
|
| [1] | JIANG Wenxin, LIU Peng. Cancer Immunotherapy and Abnormal Lipid Metabolism[J]. Cancer Research on Prevention and Treatment, 2025, 52(5): 355-360. DOI: 10.3971/j.issn.1000-8578.2025.24.1253 |
| [2] | ZHENG Yu, PAN Hongming. Progress of Targeted Therapy and Immunotherapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(4): 234-239. DOI: 10.3971/j.issn.1000-8578.2024.23.1257 |
| [3] | ZHOU Wence, ZHANG Hui, LI Xin, DONG Shi. Frontier and Future of Immunotherapy for Pancreatic Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(4): 338-344. DOI: 10.3971/j.issn.1000-8578.2023.22.1290 |
| [4] | WU Wei, JING Doudou, CAO Li, PU Feifei, SHAO Zengwu. Current Status and Prospects of Immunotherapy for Osteosarcoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(7): 721-726. DOI: 10.3971/j.issn.1000-8578.2022.21.1281 |
| [5] | CHEN Weichang, SHI Tongguo, ZHU Jinghan, SUN Linqing, LI Juntao. Progress on Immunotherapy of Gastrointestinal Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(7): 639-643. DOI: 10.3971/j.issn.1000-8578.2022.21.1527 |
| [6] | SUN Lu, SHI Hongwei, PI Guoliang. Advances in Molecular Targeting and Immunotherapy on Angiosarcomas[J]. Cancer Research on Prevention and Treatment, 2022, 49(1): 62-66. DOI: 10.3971/j.issn.1000-8578.2022.21.1045 |
| [7] | ZHOU Li, SHENG Xi'nan. Progress and Comment on Immunotherapy of Advanced Renal Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(3): 149-153. DOI: 10.3971/j.issn.1000-8578.2020.19.1519 |
| [8] | YANG Kang, LI Youyuan, YU Junfeng, WEI Shaozhong. Updates of Immunotherapy on Renal Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2015, 42(09): 929-932. DOI: 10.3971/j.issn.1000-8578.2015.09.015 |
| [9] | ZHANG Yanli, ZHU Shunqin, LIU Yaling, CUI Hongjuan. 恶性黑色素瘤内科治疗研究进展[J]. Cancer Research on Prevention and Treatment, 2014, 41(01): 74-78. DOI: 10.3971/j.issn.1000-8578.2014.01.017 |
| [10] | Wang Li, Gao Quanli, Wang Zibing, Fu Xiaomin, Zhang Xiaojie, Xu Benling, Zhang Xuhua, Zhang Yong, Yang Yonghao, Liu Yuqing, Song Yongping. Clinical Efficacy of Autologous CIK Cell Adoptive Immunotherapy Combined with Chemotherapy in Patients Withmetastatic Renal Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 722-724. DOI: 10.3971/j.issn.1000-8578.2012.06.028 |
Figures(3) / Tables(2)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: